|
|
|
|
LEADER |
02638 am a22003733u 4500 |
001 |
99380 |
042 |
|
|
|a dc
|
100 |
1 |
0 |
|a Neiman, Jaclyn A. Shepard
|e author
|
100 |
1 |
0 |
|a Massachusetts Institute of Technology. Center for Gynepathology Research
|e contributor
|
100 |
1 |
0 |
|a Massachusetts Institute of Technology. Department of Biological Engineering
|e contributor
|
100 |
1 |
0 |
|a Massachusetts Institute of Technology. Department of Chemical Engineering
|e contributor
|
100 |
1 |
0 |
|a Massachusetts Institute of Technology. Department of Materials Science and Engineering
|e contributor
|
100 |
1 |
0 |
|a Ebrahimkhani, Mohammad Reza
|e contributor
|
100 |
1 |
0 |
|a Neiman, Jaclyn A. Shepard
|e contributor
|
100 |
1 |
0 |
|a Raredon, Micha Sam Brickman
|e contributor
|
100 |
1 |
0 |
|a Griffith, Linda G.
|e contributor
|
700 |
1 |
0 |
|a Hughes, David J.
|e author
|
700 |
1 |
0 |
|a Griffith, Linda G.
|e author
|
700 |
1 |
0 |
|a Ebrahimkhani, Mohammad Reza
|e author
|
700 |
1 |
0 |
|a Raredon, Micha Sam Brickman
|e author
|
245 |
0 |
0 |
|a Bioreactor technologies to support liver function in vitro
|
260 |
|
|
|b Elsevier,
|c 2015-10-21T11:56:40Z.
|
856 |
|
|
|z Get fulltext
|u http://hdl.handle.net/1721.1/99380
|
520 |
|
|
|a Liver is a central nexus integrating metabolic and immunologic homeostasis in the human body, and the direct or indirect target of most molecular therapeutics. A wide spectrum of therapeutic and technological needs drives efforts to capture liver physiology and pathophysiology in vitro, ranging from prediction of metabolism and toxicity of small molecule drugs, to understanding off-target effects of proteins, nucleic acid therapies, and targeted therapeutics, to serving as disease models for drug development. Here we provide perspective on the evolving landscape of bioreactor-based models to meet old and new challenges in drug discovery and development, emphasizing design challenges in maintaining long-term liver-specific function and how emerging technologies in biomaterials and microdevices are providing new experimental models.
|
520 |
|
|
|a National Institutes of Health (U.S.) (R01 EB010246)
|
520 |
|
|
|a National Institutes of Health (U.S.) (P50-GM068762-08)
|
520 |
|
|
|a National Institutes of Health (U.S.) (R01-ES015241)
|
520 |
|
|
|a National Institutes of Health (U.S.) (P30-ES002109)
|
520 |
|
|
|a 5UH2TR000496-02
|
520 |
|
|
|a National Science Foundation (U.S.). Emergent Behaviors of Integrated Cellular Systems (CBET-0939511)
|
520 |
|
|
|a United States. Defense Advanced Research Projects Agency. Microphysiological Systems Program (W911NF-12-2-0039)
|
546 |
|
|
|a en_US
|
655 |
7 |
|
|a Article
|
773 |
|
|
|t Advanced Drug Delivery Reviews
|